Corbus Triggers MACD Death Cross and Bearish Marubozu on 15-Minute Chart

Based on the 15-minute chart, Corbus has triggered a MACD Death Cross and a bearish Marubozu at 11:30 on September 30, 2025. This indicates a strong potential for the stock price to continue declining, with sellers dominating the market and bearish momentum likely to persist.

Corbus Pharmaceuticals (NASDAQ:CRBP) has recently faced a significant market downturn, with the stock triggering a MACD Death Cross and a bearish Marubozu at 11:30 on September 30, 2025. This technical analysis suggests a strong potential for the stock price to continue declining, with sellers dominating the market and bearish momentum likely to persist.

The MACD (Moving Average Convergence Divergence) Death Cross occurs when the MACD line crosses below the signal line, indicating a potential bearish trend. The Marubozu, a candlestick pattern characterized by a long body with no upper or lower shadows, signals a strong bearish sentiment. These signals come at a critical time for Corbus, as the company prepares to present results from its Nectin-4 targeting ADC, CRB-701, at the upcoming European Society for Medical Oncology (ESMO) conference.

Oppenheimer has recently lowered its price target on Corbus from $60.00 to $53.00, while maintaining an Outperform rating on the stock. The stock is currently trading at $12.26, well below the analyst consensus range of $28-$55. The price target adjustment reflects the anticipation of the ESMO presentation, where Corbus will discuss results from approximately 100 additional patients treated with CRB-701, focusing on head and neck squamous cell carcinoma (HNSCC) and cervical cancer patients.

Despite the price target reduction, Oppenheimer remains optimistic about CRB-701’s potential to demonstrate a differentiated profile. The upcoming ESMO presentation is seen as an important opportunity to strengthen both safety and efficacy datasets beyond the relatively small numbers reported to date. Safety metrics, including rates of peripheral neuropathy, rash, and ocular events, remain a critical focus for CRB-701.

In other recent news, Corbus Pharmaceuticals has received an FDA Fast Track Designation for CRB-701, which is intended for treating recurrent or metastatic head and neck squamous cell carcinoma. The company has also initiated the multiple ascending dose portion of its Phase 1 trial for CRB-913, aimed at treating obesity, following the completion of the single ascending dose portion earlier in the year.

These developments highlight Corbus Pharmaceuticals’ ongoing efforts in advancing its clinical trials and drug development pipeline. However, the bearish signals in the market may indicate a period of uncertainty and volatility for the stock. Investors should closely monitor the upcoming ESMO presentation and other clinical data releases to gauge the potential impact on Corbus' stock price.